RT other
T1 Response to “Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis’”
A1 Rand, K.
A1 Ramos-Goñi, J. M.
A1 Akmaz, B.
A1 Solé-Feu, L.
A1 Armario Hita, José Carlos
A2 Medicina
AB Letter
PB Adis
SN 2190-9172
YR 2024
FD 2024-03-05
LK http://hdl.handle.net/10498/32774
UL http://hdl.handle.net/10498/32774
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 13-nov-2026